Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders

The aim of this manuscript is to review available data to evaluate the present status of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia. Relevant literature since 2003 is reviewed. The effectiveness of PCSK9 inhibitors in lowering low-densit...

Descripción completa

Detalles Bibliográficos
Autor principal: Gupta, Sanjiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108562/
https://www.ncbi.nlm.nih.gov/pubmed/27877050
http://dx.doi.org/10.2147/VHRM.S83719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108562/
https://www.ncbi.nlm.nih.gov/pubmed/27877050
http://dx.doi.org/10.2147/VHRM.S83719

Ejemplares similares